查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864381

慢性脱髓鞘多发性神经炎市场依治疗方法、最终用户、通路、患者年龄和疾病严重程度划分－2025-2032年全球预测

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，慢性脱髓鞘多发性神经炎(CIDP) 市场将成长至 39.6 亿美元，复合年增长率为 5.98%。

关键市场统计数据
基准年 2024 24.9亿美元
预计年份：2025年 26.4亿美元
预测年份 2032 39.6亿美元
复合年增长率 (%) 5.98%

简洁明了地梳理临床复杂性、治疗路径和策略重点，为相关人员在医疗、研究和商业化方面做出明智的决策提供指导。

慢性脱髓鞘多发性神经炎在临床、诊断和治疗方面具有独特的复杂性，需要综合分析以製定策略决策。本执行摘要整合了关于疾病生物学、诊疗路径、治疗方法和商业环境的最新知识，为临床医生、支付方和行业相关人员提供简洁而全面的概述。它探讨了不断发展的诊断标准、免疫疗法的进展以及医疗服务模式的改变如何相互作用，从而影响患者预后和服务使用。

本报告着重关注循证治疗实践和医疗机构的实际运作情况，将临床终点与治疗耐受性、输液基础设施以及专科诊所和居家医疗服务的容量等现实因素联繫起来。此外，引言部分概述了正在重塑竞争格局的新兴临床试验趋势和监管方法。最后，本部分为深入探讨变革性变化及其对收费系统、市场区隔资讯、区域趋势的影响，以及为负责驾驭复杂且快速变化领域的管理人员和临床领导者提供的实用建议奠定了基础。

诊断技术进步、治疗方法创新和医疗服务体系重塑如何融合，从而重新定义患者管理中的治疗方法和价值评估

慢性脱髓鞘多发性神经炎的治疗管理格局正经历着一场变革，其驱动力包括技术的成熟、监管的完善以及患者期望的改变。新型诊断方法和生物标记研究的进展正在改善病例识别和预后分层，从而支持更具针对性的治疗策略。同时，免疫球蛋白疗法製剂和给药方式的进步，以及对单株抗体和其他免疫调节剂认识的不断加深，正在拓展临床医生的选择范围，并促使人们重新评估长期治疗通讯协定。

此外，医疗系统正在调整服务模式，在临床上适宜的情况下，更加重视门诊和居家治疗。这一转变得益于皮下注射免疫球蛋白製剂和远端监测技术的进步，从而减少了对住院输液中心的依赖，并提高了患者的便利性。这一转变的趋势还包括支付者对长期治疗价值的审查，促使人们更加严格地评估疗效并管理医疗资源。这些因素正在加速向个人化、价值导向医疗保健的转变，这种医疗保健模式既重视临床疗效，也注重系统的永续性。

评估关税政策对供应链、生产策略和治疗药物可近性的影响，以及其对采购和临床决策的意义

贸易和关税政策的发展可能对用于治疗慢性脱髓鞘多发性神经炎(CIDP) 的疗法的生产经济性、供应链韧性和成本结构产生重大影响。原材料和成品生技药品的进口关税和监管要求的变化可能会使上游采购流程复杂化，并促使製造商重新评估其供应商网路和库存策略。同时，关税可能会改变生产的地域经济格局，促使製造商转移製造地或采取双重采购安排，以降低贸易中断的风险。

这些发展也可能对相关人员产生后续影响。医院药局、专科诊所和分销管道可能面临采购前置作业时间和价格压力的变化，需要对合约和库存管理进行调整。临床医生和医疗系统可能会遇到产品供应波动，这可能会影响多种静脉注射和皮下给药方式的治疗选择。因此，策略规划应纳入情境分析，评估关税对供应连续性、产品成本以及居家照护和中心给药的营运可行性的影响。同时，各机构应与支付方合作，制定符合新成本结构的报销模式。

将治疗特征、护理环境、通路、年龄组和严重程度阶段与临床和营运决策框架联繫起来的详细細項分析

细分市场分析揭示了关键的营运和临床挑战，这些挑战因治疗方法、护理环境、分发机制、患者年龄层和疾病严重程度而异。就治疗方法而言，治疗组合包括皮质类固醇、免疫抑制剂（如硫唑嘌呤、Azathioprine、Mycophenolate Mofetil和Rituximab）、静脉注射免疫球蛋白、血浆置换和皮下注射免疫球蛋白，每种方案的剂量要求、监测需求和安全性特征各不相同，这些都会影响治疗中心的选择和资源分配。在此背景下，不同的免疫抑制剂亚型可能需要专门的监测通讯协定和病患咨询，这可能会影响专科诊所与综合医院的用药模式。

终端使用者人口统计资料细分，可以凸显居家医疗、医院和专科诊所之间在营运方面的权衡取舍。居家医疗模式优先考虑患者教育、设备相容性和远端监测，而医院则专注于输液和急诊护理能力。专科诊所通常是确诊和启动长期免疫疗法的中心，而医院、线上药房和零售药房之间通路的差异会影响配药方式、低温运输管理和患者就医途径。将患者年龄分为成人、老年人和儿童，可以揭示在安全考量、给药策略和看护者支持需求方面的差异，这些都必须纳入治疗方案中。依疾病严重程度（轻度、中度、重度）进行细分，可以进一步明确治疗顺序、干预频率和监测强度，从而影响决策路径，而这些路径又与支付方核准和护理协调要求密切相关。

全球主要区域的比较动态和策略考量正在影响治疗方案的取得、报销和提供方式。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太市场的临床实践模式、法规环境、报销框架和供应物流。在美洲，不断发展的支付模式和强大的专科医疗网络支援重点关注门诊输液服务和临床适宜的家庭给药。同时，生物製药和免疫疗法监管规定的日益明确正在推动给药平台的创新。相反，欧洲、中东和非洲某些地区在药物取得和报销方面的差异，需要製定区域策略，考虑国家药品目录、集中采购和区域生产伙伴关係。

在亚太地区，医疗基础设施的快速发展和专科医生数量的不断增长，为更多人获得先进疗法创造了机会。然而，监管路径和本地生产能力的差异仍然是挑战。在这些全部区域，以价值为导向的采购模式的转变以及对真实世界证据的日益重视，正在影响药物目录的製定和临床指南的编写。因此，新参与企业和现有供应商必须根据当地的监管、支付方和供应实际情况调整其商业化策略，同时协调其在整个地区的供应链和医学事务工作，以确保医疗服务的一致性。

持续成长需要製造商和服务提供者既竞争又合作，以协调临床证据、供应链物流和患者支援。

竞争资讯显示，活跃于该治疗领域的机构类型多样，从生产免疫球蛋白疗法的生物製药企业到提供血浆置换和家庭输液服务的专业服务供应商，不一而足。拥有临床开发专长和完善的生产及分销基础设施的公司，能够更好地应对生物製药固有的复杂低温运输和品管要求。此外，投资于病患援助计画、居家照护护理师培训和数位化药物管理工具的营业单位，能够增强其对支付方和医疗服务提供者的价值提案。

製药公司与物流供应商之间的合作，以及与学术机构合作进行上市后证据生成工作，正变得越来越普遍。这些合作有助于制定生命週期管理策略，并有助于产生支付方日益需要的真实世界资料。能够提供可扩展输注能力和简化事前核准支持的服务供应商，正受到希望最大限度减少行政负担的临床医生的青睐。总体而言，随着治疗模式的演变，那些将临床证据产生与卓越营运和相关人员参与相结合的机构，更有可能保持竞争优势。

为经营团队提供实际的策略行动，以增强证据产生、强化供应链并推动医疗服务，从而实现持续的临床和商业性成功。

为了最大限度地提高治疗效果和营运永续性，产业领导者应采取多管齐下的策略，整合临床证据开发、供应链韧性和相关人员参与。首先，应优先产生可靠的真实世界证据和有针对性的临床研究，阐明长期疗效、不同治疗方法的疗效比较以及能够解决支付方顾虑的成本效益指标。其次，应透过多元化关键原材料采购、建立区域性生产或填充包装能力以及协商灵活的物流安排来降低关税和贸易风险，从而增强供应链韧性。

第三，我们将投资医疗服务创新，透过培训、远端医疗整合和数位监测工具，扩大安全居家管理范围并支持专科诊所，从而提高患者的用药依从性并降低医疗总成本。第四，我们将利用疗效数据和病患报告指标，积极与支付者和政策制定者沟通，推动与临床价值相符的报销途径。最后，我们将建立跨部门伙伴关係，包括与学术机构和患者权益倡导组织合作，以促进指南的采纳、加强患者教育并确保不同年龄层和病情严重程度的患者都能公平地获得医疗服务。这些努力将共同建构一个基于临床信誉和营运适应性的稳健商业模式。

一种透明、多方面的研究途径，结合专家访谈、系统文献综述和迭代检验，以产生可操作的临床和营运见解。

本分析的调查方法结合了定性专家访谈、对原始文献的严格审查以及对营运和监管趋势的系统性综合分析。关键投入包括与临床专家、药房部门负责人和医疗系统管理人员的咨询，以了解当地对治疗选择、输液能力和患者管理的观点。这些访谈辅以对同行评审的临床研究、监管指南和专业学会建议的系统性审查，以确保治疗和诊断趋势是基于检验的证据。

为确保可靠性，我们采用了多方资讯来源三角验证法，并透过迭代式同侪审查进行检验。我们谨慎区分了既定的临床实践和新兴的实验方法，并识别出需要进一步研究的证据缺口。我们承认以下限制：临床指引的区域差异和真实世界数据的定性差异可能会限制某些操作推论的普遍适用性。然而，我们的调查方法强调透明度、可重复性和对临床、商业和政策决策者的实际应用性。

整合临床趋势、营运挑战和策略优势，以製定改善患者疗效和永续医疗服务的路径。

本执行摘要综合分析了影响慢性脱髓鞘多发性神经炎治疗的临床、运作和策略因素。摘要重点阐述了向个人化免疫调节策略的转变、对居家和门诊治疗模式的重视，以及真实世界证据在支持支付方参与方面日益增长的重要性。此外，分析还强调了可能影响治疗方法可及性和选择的供应链因素和政策主导压力，并重申了相关人员之间积极进行紧急时应对计画和协作的必要性。

总之，有效的应对措施需要在证据收集、物资管理和支付方合作方面采取协调一致的行动，以确保患者及时获得适当的治疗，同时使医疗系统能够有效控製成本和提升服务能力。将临床见解与切实可行的营运策略相结合的相关人员，将更有能力应对不确定性，并将科学进步转化为改善慢性神经系统疾病患者预后的成果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过推广新一代皮下注射免疫球蛋白製剂，提高患者依从性和便利性
  • 开发新型FcRn受体抑制剂，以实现CIDP患者的持续疾病缓解。
  • 整合远距神经病学平台，用于远端监测和管理慢性发炎性脱髓鞘性多发性神经病变（CIDP）症状
  • 预测性生物标记组合的进展将为CIDP管理中的个人化治疗策略提供支持
  • 患者报告结局指标在指南真实世界中慢性发炎性脱髓鞘多发性神经病变（CIDP）治疗方案调整方面正受到越来越多的关注。
  • 对影响CIDP保险覆盖决策的长期免疫疗法方案进行经济评估
  • 一种针对难治性CIDP病例中髓鞘修復机制的新型基因治疗方法
  • 引入多学科诊疗路径以降低重度CIDP急性发作期间的住院率

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章慢性脱髓鞘多发性神经炎市场（依治疗方式划分）

  • 皮质类固醇
  • 免疫抑制剂
    • Azathioprine
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • Rituximab
  • 静脉注射免疫球蛋白
  • 血浆置换
  • 皮下注射免疫球蛋白

第九章慢性脱髓鞘多发性神经炎市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 专科诊所

第十章慢性脱髓鞘多发性神经炎市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章慢性脱髓鞘多发性神经炎市场（依患者年龄划分）

  • 成人版
  • 老年人
  • 孩子们

第十二章慢性脱髓鞘多发性神经炎市场（依疾病严重程度划分）

  • 温和的
  • 缓和
  • 严重

第十三章慢性脱髓鞘多发性神经炎市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章慢性脱髓鞘多发性神经炎市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国慢性脱髓鞘多发性神经炎市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Grifols, SA
    • CSL Behring AG
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Baxter International Inc.
    • LFB SA
    • Kedrion SpA
    • Biotest AG
    • Kamada Ltd.
    • Shanghai RAAS Blood Products Co., Ltd.
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market is projected to grow by USD 3.96 billion at a CAGR of 5.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.49 billion
Estimated Year [2025] USD 2.64 billion
Forecast Year [2032] USD 3.96 billion
CAGR (%) 5.98%

Concise framing of clinical complexity, treatment pathways, and strategic priorities to orient stakeholders toward informed decisions across care, research, and commercialization

Chronic inflammatory demyelinating polyneuropathy presents distinct clinical, diagnostic, and therapeutic complexities that demand integrated analysis for strategic decision making. This executive summary synthesizes current understanding of disease biology, care pathways, therapeutic modalities, and the commercial environment to equip clinicians, payers, and industry stakeholders with a concise yet comprehensive briefing. It addresses how evolving diagnostic criteria, advances in immunotherapy, and shifts in care delivery intersect to influence patient journeys and service utilization.

By focusing on evidence-based treatment practices and operational realities across settings of care, the narrative connects clinical endpoints with real-world considerations such as treatment tolerability, infusion infrastructure, and the capacity of specialty clinics and home care services. Moreover, the introduction frames emerging clinical trial trends and regulatory approaches that are reshaping the competitive landscape. Ultimately, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation intelligence, regional dynamics, and actionable recommendations crafted for executives and clinical leaders tasked with navigating a complex, rapidly changing field.

How diagnostic advances, treatment innovation, and care delivery redesign are converging to redefine therapeutic approaches and value assessment in patient management

The landscape for managing chronic inflammatory demyelinating polyneuropathy is undergoing transformative shifts driven by technological maturation, regulatory refinement, and evolving patient expectations. Novel diagnostics and biomarker research are improving case ascertainment and prognostic stratification, which in turn support more targeted therapeutic strategies. Concurrently, advances in the formulation and delivery of immunoglobulin therapies, alongside growing experience with monoclonal antibodies and other immunomodulatory agents, are expanding clinician options and prompting reassessment of long-term management protocols.

At the same time, health systems are adjusting care delivery models to emphasize outpatient and home-based administration where clinically appropriate. This shift is facilitated by advancements in subcutaneous immunoglobulin formulations and remote monitoring technologies, which reduce reliance on inpatient infusion centers and enhance patient convenience. Transitional dynamics also include payer scrutiny around long-term therapy value, leading to more rigorous outcomes measurement and utilization management. Collectively, these forces are accelerating a move toward personalized, value-oriented care that recognizes both clinical efficacy and system sustainability.

Assessment of tariff policy effects on supply chains, manufacturing strategies, and treatment availability with implications for procurement and clinical decision making

Policy developments in trade and tariffs can exert significant influence on manufacturing economics, supply chain resilience, and the cost structure of therapies used in chronic inflammatory demyelinating polyneuropathy care. Changes to import duties or regulatory requirements for raw materials and finished biologics may increase upstream sourcing complexity, prompting manufacturers to reassess supplier networks and inventory strategies. In parallel, tariffs can shift the geographic economics of production, encouraging relocation of manufacturing nodes or the adoption of dual-sourcing arrangements to mitigate exposure to trade disruptions.

These dynamics can cascade into downstream stakeholders: hospital pharmacies, specialty clinics, and distribution channels may face altered procurement lead times or pricing pressures that necessitate adjustments in contracting and inventory management. Clinicians and health systems may experience variability in product availability, which could influence therapeutic choices between intravenous and subcutaneous formulations where multiple options exist. Consequently, strategic planning must incorporate scenario analysis of tariff impacts on supply continuity, cost of goods, and the operational feasibility of home care versus facility-based administration, while also engaging with payers to align reimbursement models with emerging cost structures.

In-depth segmentation analysis linking therapy characteristics, care settings, distribution pathways, age cohorts, and severity gradations to clinical and operational decision frameworks

Segment-specific analysis reveals differentiated operational and clinical imperatives across treatment modalities, care settings, distribution mechanisms, patient age groups, and disease severity categories. When examined by treatment modality, the therapeutic mix spans corticosteroids, immunosuppressants - including azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab - intravenous immunoglobulin, plasma exchange, and subcutaneous immunoglobulin, each with distinct administration requirements, monitoring needs, and safety profiles that influence site selection and resource allocation. In this context, immunosuppressant subtypes demand specialized monitoring protocols and patient counseling that can shape utilization patterns in specialty clinics compared with broader hospital settings.

End-user segmentation highlights the operational tradeoffs between home care, hospitals, and specialty clinics. Home care models prioritize patient education, device compatibility, and remote monitoring, while hospitals underscore infusion capacity and acute management capabilities. Specialty clinics often serve as hubs for diagnostic clarification and initiation of long-term immunotherapy. Distribution channel differentiation across hospital pharmacy, online pharmacy, and retail pharmacy affects dispensing practices, cold chain stewardship, and patient access. Patient age segmentation into adult, geriatric, and pediatric populations underscores differing safety considerations, dosing strategies, and caregiver support needs that must be integrated into treatment planning. Disease severity segmentation - mild, moderate, and severe - further informs therapeutic sequencing, frequency of interventions, and intensity of monitoring, creating decision pathways that intersect with payer authorization and care coordination requirements.

Comparative regional dynamics and strategic considerations across major global territories shaping access, reimbursement, and delivery of therapeutic options

Regional dynamics shape clinical practice patterns, regulatory environments, reimbursement frameworks, and supply logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, evolving payer models and robust specialty care networks support a focus on outpatient infusion services and home administration where clinically appropriate, while regulatory clarity around biologics and immunotherapies encourages innovation in delivery platforms. Conversely, certain jurisdictions in Europe, the Middle East, and Africa exhibit heterogeneity in access and reimbursement, prompting localized strategies that account for national formularies, centralized procurement, and regional manufacturing partnerships.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and an expanding base of specialist clinicians are creating opportunities for broader access to advanced therapies, though variability in regulatory pathways and local manufacturing capacity remains a factor. Across these regions, transitions toward value-based procurement and a greater emphasis on real-world evidence are influencing formulary decisions and clinical guidelines. Therefore, market entrants and established suppliers must calibrate commercialization strategies to local regulatory, payer, and delivery realities, while also coordinating cross-regional supply chain and medical affairs efforts to ensure consistent standards of care.

Competitive and collaborative imperatives for manufacturers and service providers to align clinical evidence, supply logistics, and patient support for sustainable growth

Competitive intelligence indicates that a diverse set of organizations - from biopharmaceutical manufacturers producing immunoglobulin formulations to specialty service providers delivering plasma exchange and home infusion capabilities - are active in this therapeutic area. Firms that combine clinical development expertise with robust manufacturing and distribution infrastructures are better positioned to meet the complex cold chain and quality control demands inherent to biologic therapies. In addition, entities that invest in patient support programs, training for home care nurses, and digital adherence tools strengthen their value proposition to payers and providers.

Partnerships between pharmaceutical companies and logistics providers, as well as collaborations with academic centers for post-marketing evidence generation, are becoming more common. These alliances support lifecycle management strategies and help build the real-world datasets that payers increasingly require. Service providers that offer scalable infusion capacity and streamlined prior authorization support gain traction with clinicians seeking to minimize administrative burden. Overall, organizations that align clinical evidence generation with operational excellence and stakeholder engagement are likely to sustain competitive advantage as treatment paradigms evolve.

Practical strategic measures for executives to enhance evidence generation, fortify supply chains, and advance care delivery to sustain clinical and commercial success

Industry leaders should pursue a multipronged strategy that integrates clinical evidence development, supply chain resilience, and stakeholder engagement to maximize therapeutic impact and operational sustainability. First, prioritize generation of robust real-world evidence and targeted clinical studies that clarify long-term outcomes, comparative effectiveness across modalities, and cost-utility measures that resonate with payers. Second, strengthen supply chain resilience by diversifying sourcing of critical raw materials, establishing regional manufacturing or fill-finish capabilities, and negotiating flexible logistics arrangements to mitigate tariff and trade risks.

Third, invest in care delivery innovations that expand safe home administration and support specialty clinics through training, telehealth integration, and digital monitoring tools to improve adherence and reduce total cost of care. Fourth, engage proactively with payers and policy makers to align reimbursement pathways with clinical value, leveraging outcomes data and patient-reported measures. Finally, cultivate cross-sector partnerships - including with academic institutions and patient advocacy groups - to accelerate guideline adoption, improve patient education, and ensure equitable access across age cohorts and severity profiles. Together, these actions create a resilient commercial model grounded in clinical credibility and operational adaptability.

Transparent, multi-source research approach combining expert interviews, systematic literature review, and iterative validation to produce actionable clinical and operational insights

The research methodology underpinning this analysis combines qualitative expert engagement, rigorous review of primary literature, and structured synthesis of operational and regulatory developments. Primary inputs included consultations with clinical specialists, pharmacy leaders, and health system administrators to capture frontline perspectives on treatment selection, infusion capacity, and patient management. These interviews were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and professional society recommendations to ensure that therapeutic and diagnostic trends are grounded in validated evidence.

To ensure reliability, findings were triangulated across multiple sources and validated through iterative expert review. Attention was given to distinguishing established clinical practice from emerging experimental approaches, and to identifying gaps in evidence where further research is warranted. Limitations are acknowledged: regional heterogeneity in clinical guidelines and the variable quality of real-world datasets can constrain the generalizability of certain operational inferences. Nonetheless, the methodology emphasizes transparency, reproducibility, and the practical applicability of insights for decision-makers in clinical, commercial, and policy roles.

Synthesis of clinical trends, operational challenges, and strategic levers that together define the pathway to improved patient outcomes and sustainable care delivery

This executive synthesis delivers a cohesive view of the clinical, operational, and strategic forces shaping care for chronic inflammatory demyelinating polyneuropathy. It underscores a shift toward personalized immunomodulatory strategies, increasing emphasis on home and outpatient delivery models, and the rising importance of real-world evidence to support payer engagement. The analysis also highlights supply chain considerations and policy-driven pressures that can influence availability and selection of therapies, reinforcing the need for proactive contingency planning and stakeholder alignment.

In closing, effective responses require coordinated action across evidence generation, supply operations, and payer engagement to ensure that patients receive timely, appropriate care while health systems manage cost and capacity. Stakeholders who integrate clinical insight with pragmatic operational strategies will be better positioned to navigate uncertainty and to translate scientific advances into improved outcomes for patients living with this chronic neurologic condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation subcutaneous immunoglobulin formulations improving patient adherence and convenience
  • 5.2. Development of novel FcRn receptor inhibitors for sustained disease remission in CIDP patients
  • 5.3. Integration of tele-neurology platforms for remote monitoring and management of chronic CIDP symptoms
  • 5.4. Advances in predictive biomarker panels enabling personalized treatment strategies for CIDP management
  • 5.5. Rising focus on patient-reported outcome measures to guide therapy adjustments in real-world CIDP care
  • 5.6. Economic evaluations of long-term immunotherapy regimens influencing payer coverage decisions in CIDP
  • 5.7. Emerging gene therapy approaches targeting myelin repair mechanisms in refractory CIDP cases
  • 5.8. Implementation of multidisciplinary care pathways reducing hospitalization rates for severe CIDP exacerbations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality

  • 8.1. Corticosteroids
  • 8.2. Immunosuppressants
    • 8.2.1. Azathioprine
    • 8.2.2. Cyclophosphamide
    • 8.2.3. Mycophenolate Mofetil
    • 8.2.4. Rituximab
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Plasma Exchange
  • 8.5. Subcutaneous Immunoglobulin

9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User

  • 9.1. Home Care
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Grifols, S.A.
    • 16.3.2. CSL Behring AG
    • 16.3.3. Octapharma AG
    • 16.3.4. Takeda Pharmaceutical Company Limited
    • 16.3.5. Baxter International Inc.
    • 16.3.6. LFB S.A.
    • 16.3.7. Kedrion S.p.A.
    • 16.3.8. Biotest AG
    • 16.3.9. Kamada Ltd.
    • 16.3.10. Shanghai RAAS Blood Products Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYE